Cassandra Hatzipantelis
University of California, Davis, Monash Institute of Pharmaceutical Sciences, Monash University Faculty of Pharmacy and Pharmaceutical Sciences
0000-0001-5376-7887
About
Dr Cassandra (Cassie) Hatzipantelis is a postdoctoral research fellow with a keen interest in understanding, developing, and advancing novel therapeutic agents for the treatment of neuropsychiatric disorders. They have a PhD in Drug Discovery Biology from Monash University, Australia where she studied the efficacy and molecular mechanisms of a novel class of therapeutics to treat schizophrenia. Her work during her PhD was critical to the establishment of the Neuromedicines Discovery Centre spin-out biotech company, Phrenix Therapeutics, wherein the pipelines and frameworks Cassie spearheaded the development of are currently in use to design and test novel, safe and effective antipsychotic and procognitive agents. Now in the Olson Lab and as a research fellow for the IPN, Cassie works on various projects related to the pharmacology of psychedelic drugs and their role in neurophysiology, neuropsychiatric pathophysiology, and in the treatment of neuropsychiatric disorders.
Employment
-
University of California, Davis Postdoctoral Scholar2022 - Present
-
Monash Institute of Pharmaceutical Sciences Postdoctoral research fellow2022 - 2022
-
Monash University Faculty of Pharmacy and Pharmaceutical Sciences Teaching Assistant2018 - 2022
-
Monash Institute of Pharmaceutical Sciences Research Assistant2017 - 2018
Education
-
Monash Institute of Pharmaceutical Sciences Doctor of Philosophy2018 - 2022
-
Monash University Faculty of Pharmacy and Pharmaceutical Sciences Bachelor of Pharmaceutical Science Advanced with Honours2014 - 2017
Projects & Funding
Projects & funding information is unavailable.
Publications (11)
- R-MDDMA is a Safer Analogue of MDMA with Therapeutic Potential Save
- Indolethylamine N-Methyltransferase Deletion Impacts Mouse Behavior without Disrupting Endogenous Psychedelic Tryptamine Production Save
- Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring Save
- Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential Save
- Enhancement of Haloperidol-Induced Catalepsy by GPR143, an l-DOPA Receptor, in Striatal Cholinergic Interneurons Save
- The Effects of Psychedelics on Neuronal Physiology Save
- Gpr88 Deletion Impacts Motivational Control Without Overt Disruptions to Striatal Dopamine Save
- Molecular insights into orphan G protein‐coupled receptors relevant to schizophrenia Save
- Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia Save
- β-Arrestin-2-Dependent Mechanism of GPR52 Signaling in Frontal Cortical Neurons Save